MTLS: 3D-printing software refocuses for a leaner next chapter

The thesis

Materialise (MTLS) is a small Belgian 3D-printing specialist that’s in the middle of a “clean‑up and refocus” phase that could set up better profits from 2025 onward. In Q1 2026, revenue slipped to about €61–62M as the company exited lower‑margin manufacturing contracts and reorganized its three segments, but operating profit improved thanks to cost cuts and more focus on software and medical solutions. Management is rolling out new versions of its Magics and Mimics software platforms, tightening spending, and pushing higher‑value work in healthcare and industrial customers. If they can grow these sticky software and medical-service streams while keeping costs under control, today’s sub‑$400M valuation leaves room for upside if growth re-accelerates into 2025–2026.

💡 Why this matters

If you believe factories, hospitals, and device makers will keep shifting from old‑school manufacturing to digital, on‑demand 3D printing, Materialise sits right in that lane. Its software helps engineers and surgeons design lighter, more efficient parts and custom medical implants, which can cut waste and shipping and support climate and efficiency goals. As more companies and hospitals look to local, on‑demand production instead of huge centralized plants, the tools that plan and run those 3D‑printing jobs become critical—and that’s where Materialise makes its money.

▲ Catalysts

+ Q2 2026 earnings call: watch for revenue growth to turn positive after exiting low‑margin contracts and finishing cost cuts.
+ Progress updates on 2024–2025 cost-optimization program and segment realignment impact on margins and cash flow.
+ Adoption of new Magics and Mimics software releases by big industrial and hospital customers, showing stickier, higher‑margin software sales.
+ New healthcare partnerships or regulatory approvals for 3D‑printed medical devices using Materialise software workflows.
+ Any M&A or asset sales as management reshapes the service portfolio toward higher‑value, less commoditized work.

▼ Risks

! 3D‑printing demand can be lumpy; slower factory or hospital budgets could stall growth just as they finish restructuring.
! Larger competitors in 3D printing software and services may undercut pricing or win key customers away.
! If cost cuts go too far, service quality or innovation in new software releases could suffer.
! Currency swings (euro vs. dollar) and European economic softness could pressure reported results for U.S. investors.

🎯 One thing to take away

MTLS is a small, focused 3D‑printing software and services company that’s cleaning up its business: cutting weaker contracts, slimming costs, and pushing harder into higher‑value software and medical work. That makes the near‑term numbers a bit messy—sales are not booming yet—but the quality of revenue and profits could improve if the plan works. For everyday investors, this is more of a “turnaround in progress” than a hot momentum story. If you’re interested in the long‑term shift toward digital, on‑demand manufacturing and custom medical devices, MTLS is worth putting on a watchlist and checking back against each quarterly update to see if growth and margins are moving in the right direction.

Sources

Want our premium picks too?

Pro subscribers get our strongest pre-pop ideas + real-time buy-zone alerts.